Net sales and adjusted EBITA were around 2-3% above market consensus (LSEG) in Q3. Reported growth of 32% y/y was supported by acquisitions. Scanfil’s profitability (EBITA margin) remained healthy in Q3. Organic growth was 8.5% in the quarter, with the Americas delivering the strongest organic revenue growth. Defense sector has been 11% of net sales in 2026. Availability of components is getting harder. The value of new projects won during Q3 was EUR 48m. Increasing working capital has burden cash flow. Full-year 2026 guidance is unchanged. With a resilient margin profile and a supportive growth story relative to peers, the risk/reward remains attractive, we believe. Scanfil's customer base is expanding, organic growth is healthy, cost control is good and the balance sheet enables further acquisitions. Given the company's strong track record of strategy execution, we do not see materially higher risks ahead. The company aims to outperform the EMS market through exposure to sectors such as defense, energy, and medtech. Overall, we see the risk/reward attractive.